-1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
-1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
-1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1
-1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1
-1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1
-1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1
-1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1
-1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1
-1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1
-1 	|BT| (S (NP (JJ Genetic) (NN analysis) (NN C/EBPalpha) (NN gene) (NN progress)) (VP (ADVP (RB fully)) (VB evaluate) (NP (ADJP (NN role) (JJ novel)) (NN tumor) (NN suppressor) (NN lung) (NN cancer)))) |ET| |BS|15:F01.829.316.616 206:G05.360.340.024.340.375.249 225:E05.337 259:D12.776.395.240.150.500 260:E01.370.225.562|ES| 7:1 9:1 18:1 19:1 31:1 328:1 661:1 700:1 886:1 887:1 888:1 889:1 890:1 891:1
-1 	|BT| (S (NP (JJ Preneoplastic) (JJ neoplastic) (NNS hepatocytes)) (VP (VBP undergo) (NP (NN c-Myc) (NN up-regulation) (NN overgrowth) (NN rat)) (NP (NP (RB genetically) (JJ susceptible) (NN hepatocarcinogenesis)) (, ,) (NP (JJ resistant) (NN rat))))) |ET| |BS|8:C04 142:I01.880.604 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 261:C23.550.291.687.500 262:A11.436.348|ES| 2:1 19:1 427:1 824:1 849:1 892:1 893:1 894:1 895:1 896:1 897:1 898:1 899:1 900:1
-1 	|BT| (NP (NP (NP (DT The) (NN HER2/neu) (NN oncogene) (JJ important) (JJ diagnostic) (JJ prognostic) (NN factor)) (NP (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236 52:E02 63:G05.360.340.024.340.375.500.791.295.305 263:E01|ES| 18:1 19:1 23:1 24:1 160:1 185:1 541:1 691:1 884:1 901:1 902:1 903:1
-1 	|BT| (S (NP (DT A) (JJR better) (NN understanding) (NN mechanism) (NN Cby) (NN gene) (NN activation) (NN LSCC)) (VP (MD could) (VP (VB provide) (NP (JJ potential) (JJ novel) (JJ therapeutic) (NN target) (JJ human) (JJ laryngeal) (NN carcinoma))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 259:D12.776.395.240.150.500 264:G05.355.315.800 265:C04.557.470.200 266:E07.695.450 267:A04.329|ES| 9:1 19:1 36:1 69:1 160:1 162:1 225:1 304:1 541:1 711:1 827:1 891:1 904:1 905:1 906:1 907:1 908:1 909:1
-1 	|BT| (S (NP (NP (DT A) (JJ functional) (JJ genomic) (NN approach)) (VP (VBG integrating) (NP (NP (NN microarray) (JJ proteomic) (NN analysis)) (VP (VBN done) (NP (NN laboratory)))))) (VP (VBD identified) (NP (JJ 14-3-3zeta) (JJ putative) (NN oncogene)) (WHNP (WHNP (WP$ whose) (NN activation)) (NP (JJ common) (VBN driven) (JJ genomic) (NN amplification) (NN lung) (NN adenocarcinoma))))) |ET| |BS|9:G05.360.340.024.340.375.500 66:F01.658.293 268:H01.158.273.180.350 269:G05.360.340 270:H01.158.201.843 271:N02.278.487|ES| 19:1 24:1 69:1 225:1 255:1 328:1 415:1 623:1 655:1 661:1 910:1 911:1 912:1 913:1 914:1 915:1 916:1 917:1 918:1 919:1 920:1 921:1
-1 	|BT| (S (NP (DT A) (NN relationship) (JJ renal) (NN tumor) (NN ASPS)) (ADVP (RB initially)) (VP (VBD suggested) (NP (JJ cytogenetic) (NN finding) (JJ balanced) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;)) (NP (CD q25)) (-RRB- -RRB-) (SBAR (S (NP (NP (CD two) (NN case)) (, ,) (NP (NN ASPL-TFE3) (NN fusion) (NN transcript))) (VP (VBD confirmed) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction))))))) |ET| |BS|272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888|ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1
-1 	|BT| (NP (NNS Aberrations) (NP (NP (NP (JJ fragile) (NN histidine) (NN triad)) (PRN (-LRB- -LRB-) (NP (NN FHIT)) (-RRB- -RRB-))) (NN gene) (JJ idiopathic) (JJ pulmonary) (NN fibrosis))) |ET| |BS|6:G05.360.340.024.340 276:C08.381.483.487.500 277:D12.125.072.329|ES| 9:1 10:1 14:1 19:1 942:1 943:1 944:1 945:1 946:1 947:1 948:1 949:1
-1 	|BT| (S (NP (VBG Activating) (NP (NN alteration) (NN variety) (JJ potential) (JJ oncogenic) (NN driver) (NN gene))) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NNP NSCLC)) (, ,) (PP (VBG including) (NP (NN ROS1))) (, ,) (NP (NNP RET)) (, ,) (NP (NN MET)) (, ,) (NP (NN HER2)) (, ,) (NP (NN BRAF))))) |ET| |BS|18:G05.365.590 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 279:D27.888.569.100|ES| 2:1 5:1 9:1 19:1 188:1 329:1 561:1 623:1 827:1 950:1 951:1 952:1 953:1 954:1 955:1 956:1 957:1 958:1
-1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NN status) (NP (NP (JJ clinical) (NN significance) (JJ anaplastic) (NN lymphoma) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ALK)) (-RRB- -RRB-))) (NN gene) (NP (NP (NN alteration) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 104:C04.557.470.200.025.255|ES| 9:1 10:1 14:1 19:1 84:1 104:1 120:1 303:1 304:1 416:1 441:1 470:1 557:1 591:1 828:1 951:1 959:1 960:1 961:1 962:1
-1 	|BT| (NP (NP (NN ALK) (NN gene) (NN copy) (NN number)) (NP (NN gain) (JJ clinical) (NN significance) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 280:G05.380.350|ES| 9:1 19:1 84:1 303:1 304:1 557:1 646:1 962:1 963:1 964:1
-1 	|BT| (S (NP (DT All) (NN fusion)) (VP (VBD identified) (SBAR (S (NP (NP (NNP RET) (NN KIF5B) (NN gene)) (, ,) (NP (NP (NNP RET) (NN fusion) (NN CCDC6) (NN NCOA4) (NN gene)) (, ,) (NP (JJ characteristic) (NN thyroid) (NN cancer)) (, ,))) (VP (VBD identified) (NP (JJ irradiated) (NN lung) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815|ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJ additional) (NN study) (NN animal) (NN model)) (VP (VBN needed) (, ,))) (VP (VBG finding) (VP (VBP suggest) (S (VP (VBG targeting) (NP (NN HMGA2))))))) (VP (MD could) (SBAR (S (NP (RB therapeutically) (JJ beneficial) (NN lung) (NN cancer) (NN cancer)) (VP (VBD characterized) (NP (VBN increased) (NN HMGA2) (NN expression))))))))) |ET| |BS|283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598|ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NN CTCF)) (VP (VBD described) (NP (NP (NP (ADJP (RB significantly) (VBN mutated)) (NN gene) (JJ endometrial) (NN cancer) (NN TCGA)) (, ,) (NP (NN A) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NN track))) (SBAR (S (NP (JJ variant) (VBG leading) (NN T204) (NNS frameshifts)) (VP (VBD reported))))))))) |ET| |BS|6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265|ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1
-1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NN therapy)) (VP (VBG targeting) (NP (JJ high) (NN EphA1) (NN expression)))) (VP (VBP seem) (NP (JJ plausible) (NN CRC))))) (, ,) (S (NP (NN loss) (NN expression)) (VP (VBD advanced) (NP (NN disease)))) (VP (VBZ suggests) (SBAR (S (NP (NP (NP (JJ potential) (NN risk)) (VBN targeted) (NN therapy)) (, ,) (VP (VBG selecting) (NP (NN loss) (NN expression))) (, ,)) (VP (MD might) (VP (VB contribute) (NP (NN disease) (NN progression)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288|ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1
-1 	|BT| (S (PP (IN Among) (NP (ADJP (RB frequently) (VBN deleted)) (JJ chromosomal) (NN site))) (, ,) (NP (NN LOH) (NN chromosome) (NN 3p)) (VP (VBD detected) (NP (NN MM)) (, ,) (S (VP (VBG suggesting) (S (NP (NN presence)) (NP (CD one) (NP (JJ several) (NN tumour) (NN suppressor) (NN gene) (JJ important) (NN role)) (NN development) (NN disease))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 206:G05.360.340.024.340.375.249 289:A11.284.187 290:G05.365.590.029.530 291:F03.625.421|ES| 2:1 9:1 19:1 31:1 35:1 262:1 346:1 698:1 700:1 902:1 998:1 1000:1 1001:1 1002:1 1003:1 1004:1 1005:1 1006:1 1007:1 1008:1 1009:1 1010:1 1011:1
-1 	|BT| (S (NP (NN Amplification) (NN over-expression) (NN MAP3K3) (NN gene) (JJ human) (NN breast) (NN cancer)) (VP (VBZ promotes) (NP (NN formation) (NN survival) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|20:G03.495 55:B01.050.150.900.649.801.400.112.400.400 108:G04.299.316 155:G05.355.310|ES| 9:1 18:1 19:1 23:1 36:1 43:1 94:1 274:1 298:1 1012:1 1013:1 1014:1
-1 	|BT| (S (NP (DT An) (JJ integrative) (NN bioinformatics) (NN analysis) (NN region)) (VP (VBN nominated) (NP (NN MAP3K3) (NN gene) (JJ potential) (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 10:A01.236 12:Z01.542.049 52:E02 240:H01.158.273.180 292:Z01|ES| 9:1 18:1 19:1 23:1 160:1 541:1 661:1 667:1 827:1 830:1 1014:1 1015:1 1016:1 1017:1
-1 	|BT| (S (NP (NN Analysis) (NN TP53) (NN CTNNB1) (NN gene) (NN mutation)) (NP (NNP HG) (NN component) (NNS MASCs)) (ADVP (RB well)) (NP (NN detection) (NN copy) (NN number) (NN aberration) (NN EGFR) (NN CCND1) (NN gene)) (VP (VBP harbor) (NP (NN abnormality)))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 23:D12.776.091.249 254:C16.131 293:D01.268.556.504 294:G05.360.340.024.340.137|ES| 9:1 19:1 34:1 119:1 187:1 646:1 787:1 963:1 1018:1 1019:1 1020:1 1021:1 1022:1 1023:1 1024:1 1025:1 1026:1 1027:1
-1 	|BT| (NP (NP (PP (IN As) (NP (NN result))) (, ,) (NP (NP (NN CDCA1) (JJ novel) (NN cancer-testis) (NN antigen) (JJ overexpressed) (NN LC)) (, ,) (NP (JJ cholangiocellular) (NN cancer)) (, ,) (NP (JJ urinary) (NN bladder) (NN cancer) (JJ renal) (NN cell) (NN cancer)) (, ,) (NP (NN CDCA1)) (VP (MD may) (ADVP (RB therefore)) (NP (JJ ideal) (NN TAA) (JJ useful) (NN diagnosis) (NN immunotherapy) (NN cancer)))))) |ET| |BS|259:D12.776.395.240.150.500 263:E01 295:C04.557.470.200.025.390 296:D02.065.064.786 297:C14.907.055.239.125 298:E02.095.465.425 299:D23.050|ES| 2:1 18:1 19:1 25:1 94:1 101:1 168:1 218:1 491:1 564:1 891:1 922:1 1028:1 1029:1 1030:1 1031:1 1032:1 1033:1 1034:1 1035:1 1036:1 1037:1 1038:1
-1 	|BT| (S (PP (IN As) (NP (NP (NN Bim) (NN expression) (JJ critical) (NN biomarker) (NN response)) (NP (JJ many) (VBN targeted) (NN therapy)))) (, ,) (NP (NN PTK6) (NN inhibition)) (VP (MD may) (VP (VB offer) (NP (NP (JJ therapeutic) (NN approach)) (VP (VBG treating) (NP (NN patient) (NN Her2) (VBN targeted) (JJ therapy-resistant) (NN breast) (NN cancer))))))) |ET| |BS|43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101|ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1
-1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NN MUC4) (VBN cloned) (JJ tracheobronchial) (NN mucosa) (NN cDNA)) (ADVP (RB reportedly)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NP (JJ human) (NN malignancy)) (, ,) (PP (VBG including) (NP (NN lung) (NN carcinoma)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 182:A04.411 265:C04.557.470.200 300:D13.444.308.497.220 301:A11.251.353 302:A10.615.550|ES| 2:1 6:1 19:1 36:1 49:1 104:1 304:1 328:1 561:1 579:1 626:1 1046:1 1047:1 1048:1 1049:1 1050:1 1051:1
-1 	|BT| (NP (NP (NP (JJ Basal) (NN cell) (NN carcinosarcoma) (NN PTCH1) (NN mutation)) (NP (JJ epithelial) (JJ sarcomatoid) (JJ primary) (NN tumor) (NN component) (JJ sarcomatoid) (NN metastasis)))) |ET| |BS|8:C04 18:G05.365.590 41:A11 113:C04.697.650 303:C04.557.450.795 304:C04.557.435.290|ES| 7:1 19:1 34:1 94:1 127:1 344:1 806:1 1021:1 1052:1 1053:1 1054:1 1055:1
-1 	|BT| (S (VP (JJ BCL2-like) (NP (NP (CD 11) (NN intron) (CD 2) (NN deletion) (NN polymorphism)) (VP (VBN associated) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN risk) (NN prognosis)))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 61:E05.318.740.600.800 110:C04.588.894.797.520.109.220.249 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 18:1 19:1 94:1 148:1 169:1 171:1 328:1 544:1 694:1 1056:1 1057:1 1058:1 1059:1 1060:1
-1 	|BT| (S (NP (NN CD133)) (VP (VBN considered) (S (NP (NP (JJ stem-like) (NN cell) (NN marker) (NN cancer)) (PP (VBG including) (NP (NP (JJ gastric) (NN cancer)) (, ,) (NP (NP (NN Notch1) (NN signaling)) (VP (VBN known) (NP (NN play) (JJ important) (NN role) (NN maintenance) (NN differentiation) (JJ stem-like) (NN cell)))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 74:G04.299.151 79:I03.450.642.693 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937|ES| 2:1 18:1 19:1 31:1 86:1 94:1 195:1 215:1 238:1 534:1 556:1 561:1 651:1 652:1 902:1 1061:1 1062:1 1063:1
-1 	|BT| (NP (NP (NN Characterization) (JJ tumor-suppressive) (NN function) (NN SOX6) (JJ human) (NN esophageal) (JJ squamous) (NN cell) (NN carcinoma))) |ET| |BS|8:C04 55:B01.050.150.900.649.801.400.112.400.400|ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1
-1 	|BT| (S (NP (NN Chemokine) (NN gene) (NN expression) (JJ clonal) (NN analysis) (NN B) (NN cell) (NN tissue)) (VP (VBN involved) (NP (JJ lymphoid) (JJ interstitial) (NN pneumonitis) (JJ HIV-infected) (JJ pediatric) (NN patient)))) |ET| |BS|50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670|ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1
-1 	|BT| (S (NP (JJ Chromosomal) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ close) (JJ genetic) (NN relationship) (NN papillary) (JJ urothelial) (JJ choriocarcinomatous) (NN tumor) (NN component)) (, ,) (VP (VBG documenting) (NP (JJ first) (NN time) (NN choriocarcinoma) (JJ renal) (NN pelvis)))) (VP (VBP result) (NP (JJ clonal) (NN evolution) (JJ urothelial) (NN carcinoma) (NN acquisition) (JJ trophoblastic) (NN differentiation))))))) |ET| |BS|8:C04 74:G04.299.151 149:G05.360.340.024.340.364.875.890 289:A11.284.187 316:C04.557.465.955.207 317:C04.557.470.200.430 318:A05.810.453.537 319:A11.382.992 320:G04.299.350 321:A10.272.850 322:G01.910|ES| 2:1 7:1 19:1 101:1 215:1 223:1 275:1 304:1 661:1 816:1 864:1 922:1 1021:1 1069:1 1075:1 1076:1 1077:1 1078:1 1079:1 1080:1 1081:1 1082:1 1083:1 1084:1 1085:1 1086:1
-1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
-1 	|BT| (S (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root)))) (NP (VBD suggested) (NN B))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 272:1 412:1 534:1 661:1 763:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1
-1 	|BT| (S (NP (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root))))))) (VP (VBD suggested) (SBAR (S (NP (NNP B.) (JJ thuringiensis-induced) (NN defense) (NN system)) (VP (VBD activated) (NP (NP (NN leaf)) (, ,) (NP (NN stem)) (, ,) (NP (JJ main) (NN root) (NN tissue)) (, ,) (NP (JJ lateral) (NN root) (NN tissue)))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 309:A18.024.937 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650 329:A14.549.167.900.750 330:A18.024.812|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 163:1 272:1 412:1 534:1 593:1 661:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1 1102:1 1103:1 1104:1 1105:1 1106:1 1107:1 1108:1
-1 	|BT| (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (VP (NN DCAMKL-1) (NP (JJ negative) (NN regulator) (NN let-7a) (NN miRNA) (NN biogenesis) (JJ intestinal) (NN stem) (JJ colorectal) (NN cancer) (NN cell)))) (: ;)) (VP (MD could) (VP (VB represent) (NP (JJ novel) (NN target) (JJ anti-cancer) (NN stem) (JJ cell-based) (NN strategy))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 47:A03.556.124 184:D13.150.650.319 259:D12.776.395.240.150.500 309:A18.024.937 331:G16.595 332:A11.872.650 333:D01.045|ES| 17:1 18:1 19:1 94:1 104:1 109:1 160:1 217:1 235:1 239:1 449:1 799:1 840:1 891:1 908:1 1106:1 1109:1 1110:1 1111:1 1112:1 1113:1 1114:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Expression) (NN ra) (NN protein) (NN type) (CD II) (JJ alveolar) (NNS pneumocytes) (NN mutation) (NN codon) (CD 12) (JJ K-ras) (NN gene) (NN lung) (NN tissue)) (VP (MD may) (VP (VB contribute) (NP (NN induction) (NN lung) (NN carcinoma) (NN patient) (NN IPF)))))) |ET| |BS|18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765|ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (NN Jab1) (NN expression)) (, ,) (NP (ADVP (RB well)) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN upregulation)) (, ,) (NP (JJ evident) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN Jab1)) (VP (MD could) (NP (JJ diagnostic) (NN marker) (NN treatment) (NN target) (JJ precancerous) (NN lesion) (JJ early) (NNS HCCs))))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 158:D23.101 249:G05.355.315.800 263:E01 338:D12.644.360.225.600 339:G02.111.087.880 340:C17.800.229.400 341:C04.834|ES| 2:1 10:1 14:1 19:1 104:1 115:1 160:1 239:1 534:1 546:1 787:1 900:1 903:1 908:1 1009:1 1123:1 1124:1 1125:1 1126:1 1127:1 1128:1 1129:1 1130:1 1131:1 1132:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Reduction) (NN ING1b) (NN gene) (NN expression)) (VP (VBN associated) (VP (VBD reduced) (NP (NN p21) (NN bax) (NN gene) (NN expression) (NNS NSCLCs)))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400|ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (CD two) (NN library)) (ADVP (RB differentially)) (VP (VBD expressed) (SBAR (S (NP (NN gene)) (VP (MD may) (VP (VB provide) (NP (NN basis) (JJ new) (NN insight) (NN clue) (NN finding) (JJ novel) (NN lung) (JJ cancer-related) (NN gene)))))))) (: ;) (S (NP (JJ several) (NN gene)) (ADVP (RB newly)) (VP (VBD found) (NP (NP (NN lung) (NN cancer) (NN ERGIC3)) (VP (VBG seeming) (NP (JJ novel) (NN lung) (JJ cancer-related) (NN gene))))))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438|ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (DT This) (NN panel)) (SBAR (S (NP (JJ variant-specific) (, ,) (JJ quantitative) (NN RT-PCR) (NN assay)) (VP (VBZ detects) (NP (NP (JJ common) (NN EML4-ALK) (CC +) (JJ variant) (RB well) (NN ALK) (NN gene) (NN expression) (NN level)) (JJ archival) (JJ formalin-fixed) (JJ paraffin-embedded) (NN NSCLC) (NN specimen))))))) |ET| |BS|106:E05.091 110:C04.588.894.797.520.109.220.249 155:G05.355.310 272:E05.393.620.500.725 345:E01.370.225.500.620.720.610 346:E05.393.620.500.706 347:D02.047.407 348:K01.400.152|ES| 2:1 9:1 19:1 104:1 115:1 239:1 249:1 310:1 329:1 510:1 655:1 787:1 807:1 817:1 962:1 990:1 1147:1 1148:1 1149:1 1150:1 1151:1 1152:1 1153:1 1154:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (PRP We)) (VP (VBD provided) (NP (JJ first) (NN evidence) (NN SOX6) (JJ novel) (JJ tumor-suppressor) (NN gene) (NN ESCC) (NN development) (JJ potential) (JJ prognostic) (NN marker) (NN ESCC)))) |ET| |BS|149:G05.360.340.024.340.364.875.890 158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 19:1 35:1 38:1 104:1 239:1 534:1 816:1 827:1 843:1 884:1 891:1 1065:1 1155:1 1156:1 1157:1
-1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
-1 	|BT| (S (NP (NP (NP (NN DDR2)) (PRN (-LRB- -LRB-) (NP (NN L63V)) (-RRB- -RRB-))) (: ;) (NP (NP (NN TP53)) (PRN (-LRB- -LRB-) (NP (NN L/L)) (-RRB- -RRB-))) (NP (NN mouse))) (VP (VBD developed) (NP (NP (ADJP (RB poorly) (VBN differentiated)) (NN lung) (NN adenocarcinoma) (JJ transgenic) (NN animal)) (VP (VBN analyzed) (NP (NN latency) (CD 40) (CD 50) (NN week) (NN median) (NN survival) (CD 67.5) (NN week)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 74:G04.299.151 96:I03.784 352:B01.050.050.136|ES| 10:1 14:1 19:1 46:1 52:1 217:1 255:1 274:1 285:1 328:1 368:1 582:1 783:1 1018:1 1162:1 1163:1 1164:1 1165:1 1166:1 1167:1 1168:1 1169:1 1170:1 1171:1
-1 	|BT| (S (NP (NN DEP) (NN domain)) (VP (VP (VBG containing) (NP (CD 1) (-LRB- -LRB-) (NN DEPDC1) (-RRB- -RRB-))) (SBAR (S (NP (ADJP (RB newly) (VBN identified)) (NP (JJ cancer-related) (NN cell) (NN cycle)) (JJ related) (NN gene)) (VP (VBD demonstrated) (NP (JJ novel) (JJ therapeutic) (NN target) (NN bladder) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 259:D12.776.395.240.150.500 353:G04.299.134|ES| 9:1 10:1 14:1 18:1 19:1 94:1 98:1 160:1 286:1 419:1 541:1 564:1 601:1 623:1 891:1 1143:1 1144:1 1172:1 1173:1 1174:1 1175:1
-1 	|BT| (S (NP (NN DEPDC1)) (VP (VBD required) (NP (NN cell) (NN cycle) (NN progression) (NN motility) (JJ nasopharyngeal) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 353:G04.299.134|ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN BCL6B)) (VP (MD may) (VP (VB serve) (NP (JJ independent) (NN biomarker) (NN prognosis) (NN GC))))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 491:1 532:1 544:1 554:1 883:1 885:1 1179:1 1180:1 1181:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN PAX5)) (VP (VBD utilized) (NP (JJ independent) (JJ prognostic) (NN factor) (NN GC)))))) |ET| |BS|36:G02.111.087.029.538 243:D12.776.260.645.500|ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1
-1 	|BT| (S (NP (NP (NN Detection)) (VP (VBN methylated) (NP (NN TBX5)))) (VP (MD may) (VP (VB serve) (NP (JJ potential) (NN biomarker) (NN prognosis) (NN malignancy))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 49:1 491:1 532:1 544:1 827:1 885:1 1179:1 1180:1 1183:1
-1 	|BT| (S (NP (NN Detection) (NN TFPI2) (NN methylation) (NN stool) (NN DNA)) (VP (MD may) (VP (VB act) (NP (JJ useful) (NN adjunct) (JJ noninvasive) (NN strategy) (NN screening) (NNS CRCs) (NN future))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 81:E02.095.465.425.400.330.050.400 198:D13.444.308 354:I01.320 355:A12.459|ES| 19:1 81:1 246:1 491:1 666:1 1036:1 1114:1 1179:1 1184:1 1185:1 1186:1 1187:1 1188:1 1189:1 1190:1
-1 	|BT| (NP (NP (NP (NN DLGAP5) (NN overexpression) (JJ evident) (CD 25) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD 22) (CD 88))) (-RRB- -RRB-))) (NP (NP (NNP HCC) (NN specimen)) (PP (IN without) (NP (NN AFP) (NN expression)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN DLGAP5)) (VP (MD may) (NP (JJ novel) (NN biomarker) (NN HCC) (NN pathogenesis)))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 115:1 152:1 369:1 441:1 491:1 501:1 885:1 891:1 1009:1 1127:1 1154:1 1191:1 1192:1 1193:1 1194:1 1195:1 1196:1
-1 	|BT| (NP (NP (JJ Dual) (JJ therapeutic) (NN effect) (NN interferon-alpha) (NN gene) (NN therapy) (NN rat) (JJ hepatocellular) (NN carcinoma) (NN model) (NN liver) (NN cirrhosis))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 356:D12.644.276.374.440.890.250 357:C06.552.630|ES| 9:1 19:1 72:1 75:1 130:1 303:1 304:1 541:1 836:1 849:1 1197:1 1198:1 1199:1
-1 	|BT| (NP (NP (NN EGFR) (NN gene) (NN mutation) (NN ALK) (NN gene) (NN fusion) (JJ well-characterized) (JJ molecular) (NN target) (NN NSCLC))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 358:G05.360.340.024.340.375.500.791.295.300 359:G05.355.760.385|ES| 9:1 19:1 34:1 160:1 161:1 187:1 329:1 936:1 962:1 1200:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN dysregulation) (JJ leukaemic) (NN HOX) (NN code) (JJ MLL-rearranged) (NN leukaemia) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 360:N04.452.758.708.200.400.500 361:C04.557.337|ES| 19:1 52:1 72:1 1201:1 1202:1 1203:1 1204:1 1205:1 1206:1 1207:1
-1 	|BT| (S (NP (NN Evaluation) (NN RB) (NN status)) (VP (MD may) (NP (JJ useful) (JJ prognostic) (NN factor) (JJ human) (NN HCC)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 225:E05.337|ES| 19:1 36:1 185:1 416:1 441:1 491:1 884:1 1036:1 1208:1 1209:1
-1 	|BT| (S (NP (NN Expression) (NN DRD2)) (VP (VBZ Is) (SBAR (S (NP (VBN Increased) (JJ Human) (JJ Pancreatic) (JJ Ductal) (NN Adenocarcinoma) (NNS Inhibitors)) (VP (VBP Slow) (NP (NN Tumor) (NN Growth) (NNS Mice))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 362:D12.776.543.750.069.300.400.500 363:C04.557.470.200.025.232.750 364:D27.505.696.377.450|ES| 19:1 316:1 444:1 583:1 1210:1 1211:1 1212:1 1213:1 1214:1 1215:1 1216:1 1217:1 1218:1 1219:1
-1 	|BT| (S (NP (NP (NP (CD Fifty-four)) (PRN (-LRB- -LRB-) (NP (CD 73) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 74) (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient) (NN lung) (NN carcinoma) (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 46) (NN sample)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient)) (PP (IN without) (NP (NN lung) (NN carcinoma))))))))) (VP (VBD showed) (NP (NP (NNP LOH) (NNP FHIT) (NN gene)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.0001)))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN CD133) (NN DNA) (NN methylation)) (VP (VBZ seems) (VP (VBP constitute) (SBAR (S (NP (JJ abnormal) (NN promoter) (NN signature)) (VP (VBD found) (NP (NP (JJ normal) (NN brain) (NN colon)) (VP (VBN cultured) (NP (JJ primary) (NN tumor)))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 366:G02.111.087.029.538.161 367:A08.186.211|ES| 2:1 7:1 19:1 37:1 81:1 83:1 113:1 118:1 334:1 344:1 652:1 666:1 1227:1 1228:1 1229:1 1230:1 1231:1 1232:1
-1 	|BT| (S (NP (NNP Gene) (NN amplification) (NN 17q) (JJ chromosomal) (NN region)) (VP (VBN observed) (ADVP (RB frequently)) (NP (NN breast) (NN cancer)))) |ET| |BS|292:Z01 368:C23.550.210.182|ES| 18:1 19:1 23:1 261:1 667:1 698:1 921:1 1002:1 1233:1 1234:1
-1 	|BT| (S (NP (JJ Genomic) (NN Sequencing)) (VP (VBZ Identifies) (NP (NN ELF3) (NN Driver) (NNP Ampullary) (NNP Carcinoma)))) |ET| |BS|265:C04.557.470.200 268:H01.158.273.180.350 269:G05.360.340|ES| 19:1 1235:1 1236:1 1237:1 1238:1 1239:1 1240:1 1241:1
-1 	|BT| (S (NP (NN HEF1)) (VP (MD may) (VP (VB represent) (NP (NP (JJ attractive) (NN candidate) (NN drug)) (VP (VBG targeting) (NP (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 369:E02.319.300|ES| 19:1 191:1 245:1 491:1 616:1 799:1 974:1 1242:1 1243:1
-1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NN prevalence) (NN pattern) (NN mutation)) (NP (NP (CD two) (NN gene)) (, ,) (NP (NN Ha-ras) (NN beta-catenin)) (, ,)) (VP (VBN known) (NP (JJ mutational) (NN target) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 60:E05.318.308.985.525.750 216:Z01.107.084.900.425|ES| 2:1 9:1 19:1 34:1 52:1 60:1 160:1 179:1 260:1 400:1 403:1 556:1 747:1 900:1 933:1 1244:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (VBD generated) (NN mouse) (NN model) (NN lung) (NN adenocarcinoma)) (VP (VBN driven) (NP (NP (NN mutation) (NN discoidin) (NN domain) (NN receptor) (CD 2) (-LRB- -LRB-) (NN DDR2) (-RRB- -RRB-) (NN gene)) (JJ combined) (NN loss) (NN TP53)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 66:F01.658.293|ES| 2:1 9:1 10:1 14:1 19:1 32:1 34:1 52:1 72:1 73:1 148:1 164:1 186:1 255:1 328:1 400:1 920:1 1018:1 1162:1 1173:1 1245:1
-1 	|BT| (S (NP (JJR Higher) (NN frequency) (JJ inactive) (NN TP53) (NN mutation)) (ADVP (RB also)) (VP (VBN seen) (S (NP (NP (NP (JJ advanced) (NN stage) (NN tumour)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0003)))) (-RRB- -RRB-))) (NN tumour) (JJ poor) (JJ prognostic) (NN feature)) (NP (ADJP (NP (JJ vascular)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.006)))) (-RRB- -RRB-))) (NP (NP (JJ lymphatic) (NN invasion)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 159:I01.880.735.634 194:G05.355.044.250.750 213:F02.830.816.964 370:A15.382.520.301 371:A07.231|ES| 5:1 10:1 14:1 19:1 34:1 311:1 545:1 581:1 620:1 724:1 884:1 997:1 1011:1 1018:1 1129:1 1246:1 1247:1 1248:1 1249:1 1250:1 1251:1 1252:1 1253:1 1254:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NN mutation) (NN exon) (CD 3) (NN beta-catenin) (NN gene)) (VP (VBD detected) (SBAR (S (NP (CD one) (NN tumour)) (VP (VBD expressed) (NP (JJ nuclear) (NN beta-catenin) (JJ lining) (JJ polygonal) (NN component))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 372:G05.360.340.024.340.137.232|ES| 2:1 6:1 9:1 19:1 34:1 60:1 433:1 862:1 1007:1 1010:1 1011:1 1021:1 1255:1 1256:1 1257:1 1258:1
-1 	|BT| (S (NP (NN HOX) (NN gene)) (ADVP (RB frequently)) (VP (VBN dysregulated) (NP (NP (JJ human) (NN leukaemia) (NN gene) (NN rearrangement) (JJ mixed) (NN lineage) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN MLL)) (-RRB- -RRB-))) (NP (NN partner) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330|ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1
-1 	|BT| (NP (NP (NP (NN Identification) (NN trophinin) (NN enhancer) (NN cell) (NN invasion) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer))) |ET| |BS|41:A11 374:F01.393.446 375:Z01.639.100|ES| 18:1 19:1 94:1 185:1 328:1 620:1 884:1 972:1 1128:1 1129:1 1265:1 1266:1
-1 	|BT| (S (NP (NN IHH) (NN SMO)) (VP (MD may) (SBAR (S (NP (JJ useful) (NNS biomarkers) (JJ diffuse) (NN cancer)) (VP (MD may) (VP (VB show) (NP (NN growth) (NN inhibition) (NN Hh) (NN antagonist) (NN cyclopamine)))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 376:D23.101.140|ES| 18:1 19:1 102:1 103:1 429:1 491:1 653:1 1036:1 1267:1 1268:1 1269:1 1270:1 1271:1 1272:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ CF-treated) (JJ main) (NN root))) (, ,) (NP (NP (JJ CF-treated) (JJ lateral) (NN root)) (, ,) (NP (NP (NN expression) (JJ several) (JJ salicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (: -) (S (NP (JJ responsive) (JJ defense-related) (NN gene)) (ADVP (RB specifically)) (VP (VBD induced) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (JJ jasmonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN JA)) (-RRB- -RRB-))) (: -) (NP (JJ related) (NN gene) (NN expression))) (VP (CC either) (VP (VBD down-regulated) (NP (JJ induced) (NN response) (NN CF)))))))))) |ET| |BS|52:E02 142:I01.880.604 155:G05.355.310 325:Z01.058.290.100.140 326:A18.400 351:A17.360 377:D02.241.223.100.300.595.608|ES| 2:1 9:1 10:1 14:1 19:1 39:1 115:1 244:1 262:1 372:1 412:1 494:1 1100:1 1101:1 1107:1 1108:1 1273:1 1274:1 1275:1 1276:1 1277:1 1278:1 1279:1 1280:1 1281:1 1282:1 1283:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (VBN defined) (NN subset) (NN bone) (JJ soft) (NN tissue) (NN tumor)) (, ,) (PP (VBG including) (NP (JJ benign) (NN tumor))) (, ,) (S (NP (NN Akt)) (ADVP (RB frequently)) (VP (VBN overexpressed) (S (VP (VBN activated))))) (, ,) (NP (NP (NNP AKT1/2) (NN copy) (NN number)) (VP (VBN increased))))) |ET| |BS|378:D08.811.913.696.620.682.700.755 379:C04.588.839 380:A02.835.232 381:C04|ES| 2:1 7:1 19:1 25:1 47:1 163:1 244:1 272:1 561:1 646:1 680:1 698:1 963:1 1284:1 1285:1 1286:1 1287:1 1288:1 1289:1 1290:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN change) (NN level) (NN cdk4)) (VP (MD may) (NP (JJ useful) (NN biomarker) (NN detection) (NN HCC))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101|ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN WT1)) (VP (VBD expressed) (NP (NP (JJ substantial) (NN proportion) (NN HCC)) (VP (VBG contributing) (NP (NN tumor) (NN progression) (NN resistance) (NN chemotherapy)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN WT1)) (VP (MD may) (NP (JJ important) (NN target) (NN HCC) (NN treatment))))))))) |ET| |BS|8:C04 12:Z01.542.049 16:C23.550.291.656 52:E02 104:C04.557.470.200.025.255 151:E02.319 382:C04.557.435.595|ES| 2:1 6:1 7:1 19:1 48:1 160:1 244:1 441:1 491:1 495:1 546:1 902:1 1009:1 1094:1 1284:1 1292:1 1293:1 1294:1 1295:1
1 	|BT| (S (NP (NP (DT A) (NP (NP (JJ genetic) (NN basis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ well-established) (JJ major) (NN signaling) (NN pathway)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN Wnt-signaling)) (, ,) (NP (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (NN Ras) (NN pathway))) (, ,)) (VP (VBD identified) (NP (JJ essential) (NN HCC) (NN development)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 149:G05.360.340.024.340.364.875.890 503:D12.644.276.374.687|ES| 2:1 10:1 12:1 14:1 19:1 35:1 69:1 102:1 195:1 303:1 304:1 383:1 441:1 462:1 623:1 864:1 1140:1 1770:1 1771:1 1772:1 1773:1 1774:1 1775:1 1776:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN p53) (NNS Mutations)) (JJ common) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN induction) (JJ hepatic) (NN p53) (NN expression))) (VP (VBP cause) (SBAR (S (NP (NN lysis)) (VP (VBD implanted) (NP (NN hepatoblastoma) (NN cell) (JJ chimeric) (NN mouse)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200|ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1
1 	|BT| (S (ADVP (RB Instead)) (, ,) (NP (NNS data)) (VP (VBD revealed) (NP (NP (NP (NN Skp2)) (VBN regulated) (NN Myc) (NN activity)) (, ,) (NP (JJ oncogenic) (JJ potential) (NN generation) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 142:I01.880.604 279:D27.888.569.100 506:F01.829.263.315 507:D12.776.157.743|ES| 2:1 19:1 275:1 303:1 304:1 399:1 793:1 827:1 953:1 1664:1 1784:1 1785:1 1786:1 1787:1
1 	|BT| (NP (NP (NP (NN Loss) (NN miR-122) (NN cause) (JJ chronic) (NN steatohepatitis)) (NP (JJ spontaneous) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 508:C06.552.241|ES| 19:1 283:1 303:1 304:1 1779:1 1788:1 1789:1 1790:1 1791:1
1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN MAT1A)))) (VP (VBD reduced) (NP (JJ hepatic) (NN S-adenosylmethionine) (NN content) (NN hyperplasia)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ nonalcoholic) (NN steatohepatitis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 232:D02.886.030.676.180 509:C06.552.241.519 510:C23.550.444|ES| 19:1 376:1 452:1 583:1 648:1 838:1 1506:1 1791:1 1792:1 1793:1 1794:1 1795:1 1796:1
1 	|BT| (S (NP (NP (NP (NN MicroRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (, ,) (NP (ADJP (RB highly) (JJ abundant)) (JJ liver-specific) (NN miRNA)) (, ,)) (VP (VBP act) (NP (NP (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 104:C04.557.470.200.025.255 184:D13.150.650.319 206:G05.360.340.024.340.375.249 242:A03.620|ES| 2:1 7:1 10:1 14:1 19:1 246:1 303:1 304:1 441:1 626:1 700:1 840:1 1789:1 1797:1 1798:1 1799:1
1 	|BT| (S (NP (NP (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma1)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma1)) (-RRB- -RRB-))) (JJ important) (NN transcription) (NN factor)) (VP (VBN involved) (NP (NN atherosclerosis) (NN progression)))) |ET| |BS|16:C23.550.291.656 166:D12.776.930 511:C14.907.137.126.307 512:D12.776.826.239 513:C14.907.137.126|ES| 10:1 14:1 19:1 48:1 185:1 487:1 774:1 902:1 1800:1 1801:1 1802:1 1803:1 1804:1
1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
